Citations

Mayo Clinic

Showing 10 of 108551 citations.

Faculty Opinions recommendation of Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725927630.793517174 Get It

Faculty Opinions recommendation of Chimeric antigen receptor T cells for sustained remissions in leukemia.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.722007528.793517176 Get It

Faculty Opinions recommendation of Mitigating the toxic effects of anticancer immunotherapy.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718245866.793517171 Get It

Faculty Opinions recommendation of 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725829908.793517170 Get It

Faculty Opinions recommendation of Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718373311.793517169 Get It

Faculty Opinions recommendation of Cancer statistics, 2016.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726071516.793517164 Get It

Faculty Opinions recommendation of Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725794560.793517167 Get It

Faculty Opinions recommendation of Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725432487.793517165 Get It

Faculty Opinions recommendation of Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phas
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725403083.793517166 Get It

Faculty Opinions recommendation of Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.
Ansell, Stephen M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 20, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718363653.793517168 Get It